Dear Mr. Lucisano:

Please refer to your supplemental new drug application dated March 27, 2002, received March 28, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for WELLBUTRIN SR (bupropion hydrochloride) Sustained-Release Tablets 100 mg and 150 mg.

This CBE-30 supplemental new drug application provides for the GlaxoSmithKline facility in Mississauga, Canada as an alternate primary and secondary packaging site for WELLBUTRIN SR (bupropion hydrochloride) Sustained-Release Tablets.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Doris Bates, Ph.D., Regulatory Project Manager, at (301) 594-5536.

Sincerely,

Thomas F. Oliver, Ph.D.
Chemistry Team Leader, Psychiatric Drugs for the Division of Neuropharmacological Drug Products, (HFD-120)
DNDC I, Office of New Drug Chemistry Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Thomas Oliver
7/12/02 01:04:03 PM